First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-Targeted 212Pb Radioligand, in Patients with Metastatic Castration-Resistant Prostate Cancer.

212Pb-PSMA - Orano

AB-001 - Aubrak Therapeutics

FB3001 - Frontier Biotech

http://www.ncbi.nlm.nih.gov/pubmed/40081958

Caroline Stokke; Charlotte L Bakken; Eivor Hernes; Julie Bastiansen; Kjetil Berner; Lily Bouzelmat; Mona-Elisabeth Revheim; Monika Kvassheim; Roy H Larsen; Silje Selboe; Simen R Grønningsæter; Vicki L Jardine; Øyvind S Bruland

Mar 14, 2025